Literature DB >> 18256616

DNA repair pathways as targets for cancer therapy.

Thomas Helleday1, Eva Petermann, Cecilia Lundin, Ben Hodgson, Ricky A Sharma.   

Abstract

DNA repair pathways can enable tumour cells to survive DNA damage that is induced by chemotherapeutic treatments; therefore, inhibitors of specific DNA repair pathways might prove efficacious when used in combination with DNA-damaging chemotherapeutic drugs. In addition, alterations in DNA repair pathways that arise during tumour development can make some cancer cells reliant on a reduced set of DNA repair pathways for survival. There is evidence that drugs that inhibit one of these pathways in such tumours could prove useful as single-agent therapies, with the potential advantage that this approach could be selective for tumour cells and have fewer side effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18256616     DOI: 10.1038/nrc2342

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  621 in total

1.  Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.

Authors:  Pei-Chih Lee; Rajesh Kakadiya; Tsann-Long Su; Te-Chang Lee
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

2.  Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.

Authors:  Dana A Löser; Atsushi Shibata; Akiko K Shibata; Lisa J Woodbine; Penny A Jeggo; Anthony J Chalmers
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

Review 3.  Overview of base excision repair biochemistry.

Authors:  Yun-Jeong Kim; David M Wilson
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

4.  DNA repair inhibitors: where do we go from here?

Authors:  Mark R Kelley
Journal:  DNA Repair (Amst)       Date:  2011-10-02

5.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

Review 6.  Hitting the bull's eye: novel directed cancer therapy through helicase-targeted synthetic lethality.

Authors:  Monika Aggarwal; Robert M Brosh
Journal:  J Cell Biochem       Date:  2009-04-01       Impact factor: 4.429

7.  DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells.

Authors:  Ivo Teneng; Maria A Picchi; Shuguang Leng; Christopher P Dagucon; Suresh Ramalingam; Carmen S Tellez; Steven A Belinsky
Journal:  DNA Repair (Amst)       Date:  2019-04-27

8.  Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.

Authors:  Jung-Min Lee; Cody J Peer; Minshu Yu; Lauren Amable; Nicolas Gordon; Christina M Annunziata; Nicole Houston; Andrew K L Goey; Tristan M Sissung; Bernard Parker; Lori Minasian; Victoria L Chiou; Robert F Murphy; Brigitte C Widemann; William D Figg; Elise C Kohn
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

Review 9.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

10.  Molecular profiles for insular low-grade gliomas with putamen involvement.

Authors:  Chunyao Zhou; Yongheng Wang; Xing Liu; Yuchao Liang; Ziwen Fan; Tao Jiang; Yinyan Wang; Lei Wang
Journal:  J Neurooncol       Date:  2018-03-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.